Valuation: Theraclion

Market Cap 44.6M 51.49M 41.57M 38.23M 72.18M 4.9B 72.99M 489M 192M 2.45B 193M 189M 8.11B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 52.45M 60.56M 48.89M 44.97M 84.89M 5.76B 85.84M 575M 225M 2.88B 227M 222M 9.54B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day-0.97%
Current month-8.27%
1 month-8.27%
3 months-28.24%
6 months-8.96%
Current year+4.45%
1 month 0.61
Extreme 0.61
0.66
Current year 0.44
Extreme 0.435
0.87
1 year 0.44
Extreme 0.435
0.94
3 years 0.14
Extreme 0.1445
0.94
5 years 0.14
Extreme 0.1445
0.94
10 years 0.14
Extreme 0.1445
0.94
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 01/02/2018
Director/Board Member - 13/02/2019
Director/Board Member - 13/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%+3.53% - - 51.49M
-0.63%-0.33%+28.05%+4.18% 214B
-0.85%+1.34%+1.86%-22.23% 140B
-0.54%+5.76%-21.26%+20.71% 133B
+4.80%+8.79%-51.39%-1.35% 69.19B
-0.18%+2.12%+12.92%+11.18% 51.28B
-0.57%+5.03%-14.34%-19.92% 50.43B
-1.01%+0.72%+23.38%+10.43% 39.85B
-1.51%+3.74%+42.06%+36.17% 39.27B
+0.36%+7.69%-19.92%+20.32% 32.32B
Average -0.12%+3.77%+0.15%+6.61% 85.43B
Weighted average by Cap. -0.17%+3.04%+2.29%+3.23%

Financials

2024 2025
Net sales 830K 959K 774K 712K 1.34M 91.15M 1.36M 9.09M 3.57M 45.61M 3.6M 3.52M 151M 652K 753K 608K 559K 1.06M 71.58M 1.07M 7.14M 2.8M 35.82M 2.83M 2.77M 119M
Net income -5.76M -6.65M -5.37M -4.94M -9.32M -632M -9.42M -63.06M -24.75M -316M -24.97M -24.42M -1.05B -5.69M -6.57M -5.3M -4.88M -9.21M -625M -9.31M -62.33M -24.46M -313M -24.67M -24.13M -1.04B
Net Debt 3.41M 3.94M 3.18M 2.92M 5.52M 374M 5.58M 37.36M 14.66M 187M 14.79M 14.46M 621M 7.85M 9.07M 7.32M 6.73M 12.71M 862M 12.85M 86.01M 33.76M 431M 34.05M 33.3M 1.43B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change
06/08/26 0.6100 -0.97%
05/08/26 €0.6160 -0.96%
04/08/26 €0.6220 +6.51%
03/08/26 €0.5840 +1.57%
31/07/26 €0.5750 -3.36%

Annual profits - Rate of surprise